Literature DB >> 28445102

Journey of Generic Imatinib: A Case Study in Oncology Drug Pricing.

Christopher T Chen1, Aaron S Kesselheim1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28445102     DOI： 10.1200/JOP.2016.019737

Source DB:  PubMed          Journal:  J Oncol Pract        ISSN： 1554-7477            Impact factor:   3.840


× No keyword cloud information.
  7 in total

Review 1.  Targeting the B cell receptor pathway in non-Hodgkin lymphoma.

Authors:  Kelly Valla; Christopher R Flowers; Jean L Koff
Journal:  Expert Opin Investig Drugs       Date:  2018-06-07       Impact factor: 6.206

Review 2.  Chronic Hepatitis C: Do Generics Work as Well as Branded Drugs?

Authors:  Madhumita Premkumar; Gagandeep S Grover; Radha K Dhiman
Journal:  J Clin Exp Hepatol       Date:  2017-09-23

3.  Health Care Cost Associated With Contemporary Chronic Myelogenous Leukemia Therapy Compared With That of Other Hematologic Malignancies.

Authors:  Jennifer J Wilkes; Gary H Lyman; David R Doody; Shasank Chennupati; Laura K Becker; Pamela E Morin; Lena E Winestone; Henry J Henk; Eric J Chow
Journal:  JCO Oncol Pract       Date:  2020-08-21

4.  The risks of perpetuating an evolutionary arms race in drug discovery.

Authors:  Scott M Leighow; Justin R Pritchard
Journal:  Evol Med Public Health       Date:  2019-05-21

5.  Efficacy and safety of generic imatinib after switching from original imatinib in patients treated for chronic myeloid leukemia in the United States.

Authors:  Iman Abou Dalle; Hagop Kantarjian; Jan Burger; Zeev Estrov; Maro Ohanian; Srdan Verstovsek; Farhad Ravandi; Gautam Borthakur; Guillermo Garcia-Manero; Elias Jabbour; Jorge Cortes
Journal:  Cancer Med       Date:  2019-09-10       Impact factor: 4.452

6.  Evaluation of oxidative stress responses in human circulating blood cells after imatinib mesylate treatment - Implications to its mechanism of action.

Authors:  Goran Gajski; Marko Gerić; Ana-Marija Domijan; Ivana Golubović; Vera Garaj-Vrhovac
Journal:  Saudi Pharm J       Date:  2019-10-25       Impact factor: 4.330

7.  Cost-effectiveness Analysis of Genetic Testing and Tailored First-Line Therapy for Patients With Metastatic Gastrointestinal Stromal Tumors.

Authors:  Sudeep Banerjee; Abhishek Kumar; Nicole Lopez; Beiqun Zhao; Chih-Min Tang; Mayra Yebra; Hyunho Yoon; James D Murphy; Jason K Sicklick
Journal:  JAMA Netw Open       Date:  2020-09-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.